p21 (CDKN1A / WAF1 / CIP1) — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

p21 (CDKN1A / WAF1 / CIP1)

Also known as: WAF1, CIP1, SDI1, MDA-6, CDKN1A, p21WAF1/CIP1, p21Cip1, p21Waf1, Cyclin-Dependent Kinase Inhibitor 1A, RAS-p21 (distinct oncogenic GTPase — see no_data_topics note)

Cyclin-Dependent Kinase Inhibitor (CKI), CIP/KIP family; intrinsically disordered protein (IDP)

Research chemicalLast updated: October 19, 2026Based on 37 peer-reviewed studies

What it is

p21 is a naturally occurring protein that controls cell division and acts as a tumor suppressor; researchers are studying ways to restore or target it in bladder cancer, melanoma, and other cancers. It works by putting the brakes on uncontrolled cell growth. Not approved as a therapeutic; studied in early cancer research models.

The scientific side

p21 (CDKN1A/WAF1/CIP1) is a small, intrinsically disordered protein and broad-specificity inhibitor of cyclin-dependent kinase (CDK) complexes. It was originally identified as a transcriptional target of the tumor suppressor p53 and a primary mediator of p53-dependent cell-cycle arrest in response to DNA damage. By suppressing CDK activity, nuclear p21 arrests the cell cycle at G1 and G2 phases and inhibits PCNA-dependent DNA replication. p21 also possesses CDK-independent functions: residual S-phase p21 controls DNA replication speed and origin firing via direct displacement of partners from chromatin-bound PCNA. p21 protein levels are controlled at multiple layers — transcriptionally (by p53-dependent and p53-independent mechanisms including epigenetic silencing via histone methylation/deacetylation), post-transcriptionally (mRNA stability regulated by RNA-binding proteins such as AUF1 and CUGBP1, and by competing circRNAs such as circPCNX), and post-translationally (phosphorylation by kinases including AKT and CDK2; proteasomal degradation via both ubiquitin-dependent N-terminal ubiquitinylation and ubiquitin-independent 20S proteasomal degradation mediated by the PSMA3 Trapper through the RRLIF degron). Subcellular localization critically determines p21's function: nuclear p21 is generally tumor-suppressive (cell cycle arrest, senescence, genomic stability), while cytoplasmic p21 is associated with pro-oncogenic effects including inhibition of apoptosis, promotion of cancer stem cell properties via NFκB activation, and chemoresistance. Phosphorylation events (notably at T145 by AKT) drive cytoplasmic translocation. p21 also participates in cellular responses to oxidative stress through conserved cysteine-switch redox-sensing mechanisms in its Kinase Inhibitory Domain (KID), enabling direct sensing of reactive oxygen species (ROS). Beyond cell cycle control, p21 participates in regulation of autophagy, apoptosis, senescence, macrophage activation, osteoblast differentiation, metabolic processes, cardiac function, melanogenesis, and inflammatory responses.

Class: Cyclin-Dependent Kinase Inhibitor (CKI), CIP/KIP family; intrinsically disordered protein (IDP)

Administration & storage

Administration
Intravesical administration of p21 mRNA-loaded lipid nanoparticles (p21-LNP) in orthotopic mouse bladder cancer model (PMID: 42144924)Intraarticular injection of lentiviral shRNA targeting p21 in mouse cartilage defect model (PMID: 42007882)Intraperitoneal injection of LPS (5 mg/kg) to induce sepsis model in which p21 role was studied — not p21 itself (PMID: 32694519)
Storage
No abstracts in the reviewed set describe storage conditions for p21 protein or p21-based therapeutic preparations.
Cautions
p21 (CDKN1A) has a well-documented dual role as both tumor suppressor and oncogene depending on subcellular localization and cellular context — therapeutic targeting without precise localization control carries risk of paradoxical pro-tumorigenic effects (PMID: 42201575, PMID: 11880176).,Cytoplasmic p21 promotes cancer stem cell properties and chemoresistance via NFκB activation and AKT-p21 phosphorylation axis; increasing p21 expression without controlling its localization may worsen outcomes in certain cancers (PMID: 41178462, PMID: 41462552).,In an in vivo mouse cartilage repair model, lentiviral delivery of p21 shRNA resulted in minimal but detectable hepatic off-target transduction, which increased in injured animals; morphological hepatotoxicity was not observed, but off-target effects require monitoring.,p21-/- iPSCs formed tumors post-transplantation in the absence of iCasp9 activation in a mouse model; robust safety mechanisms (e.g., suicide gene systems) are required when using p21-knockout stem cells therapeutically.,No human pharmacokinetic data for exogenous p21 protein or p21 mRNA administration are reported in the reviewed literature — extrapolation of preclinical findings to clinical use is not supported by available evidence.,IMPORTANT DISAMBIGUATION: 'RAS-p21' (the oncogenic GTPase encoded by RAS genes) is a completely different protein from CDKN1A/WAF1/CIP1 p21. FDA-approved agents targeting RAS-p21 (sotorasib, adagrasib) do not act on CDKN1A p21. Confusing these two proteins in a clinical context could have serious consequences.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification. NOTE: Two FDA-approved small molecules targeting the distinct oncogenic GTPase RAS-p21 (AMG510/sotorasib and MRTX849/adagrasib) are mentioned in PMID…

WADA

Not stated in reviewed literature — requires manual verification.

Health Canada

Not stated in reviewed literature — requires manual verification.